[A clinical study of estramustine phosphate sodium for the treatment of hot flushes in men with prostate cancer].
To assess the effectiveness and tolerability of estramustine sodium phosphate in men with hot flushes during combined androgen blockade (CAB) therapy for prostate cancer. Seven men with moderate to severe hot flushes were received estramustine sodium phosphate. Treatment response was assessed by hot flush score. A significant reduction in the hot flush score was seen with all patients. No thromboembolic complications occurred in any patients. Estramustine sodium phosphate appears to be a promising, well-tolerated and useful therapy for men with hot flushes during CAB treatment for prostate cancer.